Navigation Links
Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
Date:11/20/2012

SEATTLE, Nov. 20, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the 24th Annual Piper Jaffray Health Care Conference next week.  The presentation is scheduled for 9:30 a.m. Eastern Time on Tuesday, November 27, 2012.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.  

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Omeros is Not Aware of Any Justification for Share Price Movement
2. Omeros Corporation Reports Third Quarter 2012 Financial Results
3. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
4. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
5. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
6. Omeros to Present at Two Upcoming Conferences
7. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
8. Omeros Corporation Reports Second Quarter 2012 Financial Results
9. Omeros Announces Discovery in MASP-2 Program
10. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
11. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... May 26, 2017  Endo International plc (NASDAQ: ... and CEO, will represent the Company in a fireside chat ... on Tuesday, June 13, 2017 at 10:40 a.m. PT / ... Resort in Rancho Palos Verdes, CA. ... event will be available on the Company,s website at ...
(Date:5/26/2017)... 2017  In response to the opioid epidemic in ... is working with Pfizer to make up to 1 ... to community health centers, free and charitable clinics, public ... "Pfizer has a long-standing commitment to improving health ... safety through educational activities," said Caroline Roan , ...
(Date:5/24/2017)... 24, 2017  ivWatch LLC today announced the ... Board to enable seamless integration of ivWatch,s groundbreaking ... infusion pumps and other devices. By integrating ivWatch ... to help health care customers deliver a higher ... to IV therapy. "The ivWatch OEM ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... Mediaplanet is proud to announce the launch of its ... will educate readers on how to take care of all aspects of their skin. ... on melanoma. Dancing with the Stars professional, Witney Carson, shares her journey with the ...
(Date:5/26/2017)... ... May 26, 2017 , ... The American ... review more than eighty-nine grant submissions all vying for nearly $1,000,000 in funding ... Parkinson’s field.     , The American Parkinson Disease Association (APDA) is focused on advancing ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... Boston CEO 2017 on May 30th and 31st at The Four Seasons Hotel ... leading executives in the life sciences, offering exclusive access to key decision makers ...
(Date:5/26/2017)... ... May 26, 2017 , ... The ... educational seminar to focus on current legislative activity and the latest regulatory concerns ... 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. 11, at ...
(Date:5/26/2017)... ... 26, 2017 , ... Amir Qureshi, MD is the first physician in Arkansas ... stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a treatment ... in Arkansas to introduce the most powerful SCS system and the only stretchable lead ...
Breaking Medicine News(10 mins):